James R. Berenson, MD
Oncotherapeutics
5
4
3
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
PEGOURIE, MD
University Hospital, Grenoble
Shared therapeutic areas:
Michel ATTAL, MD, PhD
University Hospital, Toulouse
Shared therapeutic areas:
AUGEL MEUNIER, MD
CHU ST PRIEST EN JAREZ
Shared therapeutic areas:
MOREL, MD
Hôpital la Pitié Salpêtrière Paris
Shared therapeutic areas:
BENBRAHIM, MD
CH ORLEANS
Shared therapeutic areas:
Areej El-Jawahri, MD
Massachusetts General Hospital
Shared therapeutic areas:
Gustavo Leone
Medical University of South Carolina, Hollings Cancer Center
Shared therapeutic areas:
WETTERWALD, MD
CH DUNKERQUE
Shared therapeutic areas:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
All 5 trials loaded